Rationale: The case report aims to discuss the clinical symptoms and treatment of encephalopathy caused by a novel syntaxinbinding protein 1 (STXBP1) genetic mutation.
Introduction
Early-onset epileptic encephalopathy refers to continuous and repeated epilepsy accompanied by abnormal brain electrical activities in the neonatal or early infant period, which can lead to retardation of progressive cognition and comprehensive motor development. [1] Recent gene sequencing studies have found an increasing number of pathogenic genes associated with earlyonset epileptic encephalopathy. In 2008, the syntaxin-binding protein 1 (STXBP1) gene was proved to be associated with earlyonset epileptic encephalopathy. [2] STXBP1 encephalopathy is caused by an abnormal STXBP1 protein encoded by the mutated STXBP1 gene. Typical characteristics of the disease are epileptic seizures and severe psychomotor development retardation that occurs within 3 months of age, usually accompanied by low muscle tension, tremble, myoclonus, spastic quadriplegia or diplegia, stereotypical movement of the head or limbs, movement disorder, and ataxia. Currently, it is believed that STXBP1 encephalopathy is a type of complex neurodevelopmental disorder rather than primary epilepsy. [3] We report a case of STXBP1 encephalopathy caused by a de novo STXBP1 genetic mutation, and review treatment effects of adrenocorticotropic hormone (ACTH) and levetiracetam as previously reported in the literature.
Case report
The patient, a girl, was born at 38 +4 weeks of gestation with a birth weight of 2650 g; her Apgar score was normal. The patient's mother had a normal pregnancy, but she had a history of spontaneous abortion. There was no family history of seizure disorders, genetic metabolic disease, and mental illness. Ethical approval was obtained from the ethics committee of West China Second University Hospital, Sichuan University. Written informed consent was obtained from the parents of the patient for publication of this case report.
The patient had her first spasm seizures 6 days after birth that manifested as sudden nodding, lifting of double upper limbs and adduction of lower limbs, lasting for a second. She was treated at a local hospital with calcium and Vitamin D, but there was no significant improvement. The seizures gradually increased and Medicine became a cluster of spasm seizures, and the patient had seizures of more than 7 to 8 clusters/day, both while being awake and sleeping (about 50 times/day). The patient was admitted to our hospital (West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China) at the age of 2 months and 17 days. Physical examination revealed the following: head circumference: 38 cm, anterior fontanel: 3.5 cm Â 3.5 cm. The patient was unable to chase light and objects, laugh, and raise her head. Muscle strength in the lower extremities was normal, but autonomous activity was reduced. The distal muscle tone was decreased but the knee tendon reflex was normal, and the patient had no positive Babinski sign or organomegaly. Laboratory tests revealed that complete blood counts and blood biochemistry (gas analysis, electrolyte, ammonia, lactate, pyruvate, and blood b-hydroxybutyric acid level) were normal. Additionally, liver and kidney function tests, hematuria tandem mass spectrometry, and brain magnetic resonance imaging revealed no abnormalities. Video electroencephalography (VEEG) indicated burst suppression pattern (Fig. 1) . Initially, valproic acid (20 mg/kg), topiramate (5 mg/kg), and vitamin B6 (40 mg/kg) were administered daily for a week; however, seizures did not reduce. Next, valproic acid was replaced with levetiracetam (20 mg/kg per day). Seizures decreased from 7 to 8 clusters/day to 2 to 3 clusters/day (about 20 times/day) after treatment with levetiracetam and topiramate for 1 week. Further, intravenous administration of adrenocorticotropic hormone (ACTH 25 u/day) in combination with levetiracetam, topiramate, and high-dose vitamin B6 was performed. After ACTH use for 4 days, seizures were completely controlled. The patient could chase light and objects, and laugh following ACTH use for 2 weeks, but still could not raise her head independently. VEEG was performed again, and showed signs of improvement ( Fig. 1) .
After the girl was discharged from the hospital, prednisone (1 mg/kg/day) was continued, but was gradually reduced and withdrawn over 3 months. At the same time levetiracetam was gradually increased to 40 mg/kg per day and was accompanied with topiramate (5 mg/kg per day).
Further, whole exome sequencing test revealed mutations in the STXBP1 gene (located on chromosome 9) and truncated c.904G>T (exon 11) and amino acid p.E302X.302 (NM_003165); however, the parents showed a wild type allele (Fig. 2 ). Copy number variation was normal. Topiramate was gradually withdrawn, and levetiracetam was continued after mutations in the STXBP1 gene were revealed. The patient had no further seizures and could raise her head at the age of 6 months. Presently, at the age of 9 months, the patient's muscle tone is still slightly decreased, and she cannot sit by herself. Although she can laugh and chase sound better than she could before, she cannot speak single syllables like "da" and "ma".
Discussion and conclusions
In 2008, the STXBP1 genetic mutation was initially discovered by Saitsu H in a patient with Ohtahara syndrome (OS).
[2] The STXBP1 gene, a member of the evolutionarily conserved Sec1/ Munc-18 gene family, mainly encodes a specific membrane transporter protein in the brain, which plays a key role in the connection and integration of synaptic vesicles-an important mechanism of neurotransmitter secretion. [4] The lack of its expression may lead to damage of the synaptic vesicles and neurotransmission function, which greatly reduces readily releasable vesicles in GABAergic neurons (gamma-aminobutyric acid, GABA) compared with glutamatergic neurons, thus leading to excessive neural network excitement and epileptic activity. [5] [6] [7] A total of 147 types of STXBP1 genetic mutations have been reported so far, including nonsense mutations, truncated mutations, and deletions. Currently, the correlation between genotype and clinical phenotype has not been established. In this case, the patient had a novel truncation mutation that has not been reported yet, and the normal codon encoding glutamic acid was mutated to a termination codon, 302 amino acids of the www.md-journal.com Table 1 Summary of ACTH effects on patients with STXBP1 mutations, as reported in the literature. 
Liu et al. Medicine (2018) 97:18 Medicine
protein sequence were shortened and thus contributing to the pathogenesis of the disorder. The parents of the patient did not carry this mutation; therefore, it is a de novo mutation. Currently, increasing number of studies have demonstrated that epilepsy and psychomotor retardation are 2 major manifestations of neurological dysfunction caused by STXBP1 genetic mutation. [8, 9] It is known that 95% of cases with the STXBP1 genetic mutation have epilepsy and early-onset epileptic encephalopathy, including OS, infantile spasms (IS), early epileptic encephalopathy with suppression bursts (EESB), and early infantile epileptic encephalopathy (EIEE). [2, 8, [10] [11] [12] Detection rates of the STXBP1 mutation in OS, West syndrome, and unclassified early-onset epilepsy encephalopathy are 21%, 9.5%, and 53%, respectively. [13] In 2010, Deprez [7] found that about 10.2% of patients with early-onset epilepsy encephalopathy had an STXBP1 mutation, suggesting that this was an important gene for early epilepsy encephalopathy. In the present case, the patient showed frequent spasm attacks 6 days after her birth that presented as sudden nodding, lifting of both upper limbs, and adduction of lower limbs. The attack progressed to cluster, and VEEG showed a burst suppression pattern.
The second major manifestation of the STXBP1 genetic mutation is psychomotor retardation. [8, 14] All patients with STXBP1 genetic mutations show varying degrees of psychomotor retardation, with 90% displaying severe psychomotor development retardation and 17% having autism and autism-like spectrum disorder. However, no specific abnormalities are observed on cranial imaging and metabolic screening for the majority of these children. Psychomotor retardation can appear as an independent clinical manifestation or along with epilepsy. [8, 13, 15] In our case, epilepsy was fully controlled by the age of 3 months, and VEEG showed improved patterns. Throughout the follow-up visits, until the age of 9 months, no convulsion seizures were observed, but psychomotor retardation and low muscle tone had not significantly improved through epilepsy control. Our case confirms that levetiracetam and ACTH can reverse the epileptogenic abnormalities, but may not be effective in altering the accompanying psychomotor development retardation caused by an STXBP1 gene mutation.
According to previous reports, the treatment of STXBP1 encephalopathy was comprehensive, including epilepsy control and neurological rehabilitation. Studies have demonstrated that epilepsy in about half of the patients could be controlled after drug administration; however, over half of the children needed treatment with 3 antiepileptic drugs. Several studies report that vigabatrin, valproic acid, topiramate, clobazam, oxcarbazepine, and ketogenic diet were effective in seizure control. [8, [16] [17] [18] [19] [20] [21] Levetiracetam was also reported to have a good effect. [8, 22, 23] In the present study, no obvious effect was seen on epileptic seizures when topamax and valproic acid were used. The frequency of seizures reduced after using levetiracetam, but could not be fully controlled, suggesting that levetiracetam was partially effective. Levetiracetam regulates synaptic vesicle release system by binding to the synaptic vesicle protein SV2A, which regulates synaptotagmin-1. Lou et al [24] reported that synaptotagmin-1 is an antagonist for Munc18-1 in SNARE zippering. Thus, levetiracetam binds to and regulates SV2A, and may counterbalance the epileptogenic effects induced by STXBP1 mutation. [22, 23] Nonetheless, these studies were based on a small number of cases, and there was no large prospective study available for verification.
With regard to the therapeutic efficacy of ACTH, we reviewed 15 reports of patients carrying an STXBP1 mutation treated with ACTH in the literature. [7, 9, 11, 12, [25] [26] [27] [28] [29] [30] and compared the therapeutic efficacy of ACTH (Table 1) . [7, 8, 10, 11, [24] [25] [26] [27] [28] [29] Among them, 4 cases were diagnosed with OS, 6 cases had IS (1 case later evolved to infantile myoclonic epilepsy), 3 cases had EESB (1 case later evolved to IS), and 2 cases had EIEE. With the exception of ACTH, 2 patients did not use any antiepileptic drugs (AEDs), 5 patients used 1 AED, while 8 patients used 3 or more AEDs. Steroid, ketogenic diet, IVIG, and surgery were used in 3, 4, 1, and 1 case, respectively. Although the sample size is small, ACTH was effective in controlling seizures; 9 cases showed complete seizure control (Patients 6 and 8 used vigabatrin at the same time), 3 cases showed partial seizure control (Patient 5 had seizure control after ACTH but relapsed 3 months later, and was seizure-free after surgery. Patient 14 had seizures disappear after ACTH but relapsed soon, seizures decreased after treatment with intravenous immunoglobulin and clobazam), and 3 cases showed no effect (Patient 3, 11 were multidrug resistant). In this case, we demonstrate seizure control with improved VEEG patterns after ACTH treatment and no seizure relapse throughout the followup for 7 months. Combined with previous cases reports, we conclude that ACTH is an effective drug for epileptic seizure control in early-onset epileptic encephalopathy caused by an STXBP1 mutation.
Briefly, in cases of early-onset epileptic encephalopathy and severe psychomotor development retardation, the STXBP1 gene should be considered as a candidate for early genetic screening. Early application of levetiracetam and ACTH may provide therapeutic benefits for epilepsy.
